Shanghai Aolu Biomedical Technology

Shanghai Aolu Biomedical Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in refractory hematological malignancies and complex autoimmune diseases. Aolu Bio leverages its proprietary cell engineering platform to design multi-target and high-persistence cell products intended to improve safety profiles and therapeutic efficacy. Their lead program, AL-101, is currently undergoing clinical evaluation for B-cell malignancies. The company aims to streamline manufacturing processes to make advanced immunotherapies more accessible to a broader patient population.